Trial Profile
A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 25 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Mar 2024.
- 04 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.